loading
前日終値:
$7.56
開ける:
$7.55
24時間の取引高:
421.09K
Relative Volume:
0.54
時価総額:
$408.83M
収益:
$8.78M
当期純損益:
$-104.70M
株価収益率:
-3.2447
EPS:
-2.37
ネットキャッシュフロー:
$-82.68M
1週間 パフォーマンス:
+17.94%
1か月 パフォーマンス:
-14.56%
6か月 パフォーマンス:
-42.05%
1年 パフォーマンス:
-34.39%
1日の値動き範囲:
Value
$7.34
$7.72
1週間の範囲:
Value
$6.415
$7.99
52週間の値動き範囲:
Value
$5.35
$17.58

Stoke Therapeutics Inc Stock (STOK) Company Profile

Name
名前
Stoke Therapeutics Inc
Name
セクター
Healthcare (1151)
Name
電話
781-430-8200
Name
住所
45 WIGGINS AVENUE, BEDFORD, MA
Name
職員
128
Name
Twitter
@stoketx
Name
次回の収益日
2025-03-18
Name
最新のSEC提出書
Name
STOK's Discussions on Twitter

STOK を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
STOK
Stoke Therapeutics Inc
7.69 408.83M 8.78M -104.70M -82.68M -2.37
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
489.10 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.16 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
596.20 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
234.56 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
230.98 26.16B 3.81B -644.79M -669.77M -6.24

Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-20 開始されました Chardan Capital Markets Buy
2024-10-14 再開されました Leerink Partners Outperform
2024-03-26 アップグレード TD Cowen Market Perform → Outperform
2023-11-20 再開されました JP Morgan Neutral
2023-07-25 ダウングレード TD Cowen Outperform → Market Perform
2023-05-01 アップグレード BofA Securities Underperform → Neutral
2023-04-26 再開されました Canaccord Genuity Buy
2023-01-06 ダウングレード BofA Securities Buy → Underperform
2022-10-24 アップグレード SVB Leerink Mkt Perform → Outperform
2022-01-31 開始されました Jefferies Buy
2021-12-03 開始されました BofA Securities Buy
2021-11-22 アップグレード JP Morgan Neutral → Overweight
2021-05-18 開始されました UBS Neutral
2021-05-10 アップグレード Wedbush Neutral → Outperform
2021-04-26 再開されました Credit Suisse Outperform
2021-02-10 ダウングレード Wedbush Outperform → Neutral
2020-12-15 再開されました H.C. Wainwright Buy
2020-12-11 繰り返されました Needham Buy
2020-10-23 開始されました Cantor Fitzgerald Overweight
2020-09-29 再開されました JP Morgan Neutral
2020-09-29 開始されました Needham Buy
2019-12-18 開始されました Wedbush Outperform
2019-11-12 開始されました BTIG Research Buy
2019-10-25 開始されました H.C. Wainwright Buy
2019-07-15 開始されました Canaccord Genuity Buy
2019-07-15 開始されました Cowen Outperform
2019-07-15 開始されました Credit Suisse Outperform
2019-07-15 開始されました JP Morgan Overweight
すべてを表示

Stoke Therapeutics Inc (STOK) 最新ニュース

pulisher
Apr 17, 2025

Leerink Partnrs Issues Optimistic Estimate for STOK Earnings - Defense World

Apr 17, 2025
pulisher
Apr 16, 2025

Analysts Are More Bearish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Than They Used To Be - simplywall.st

Apr 16, 2025
pulisher
Apr 16, 2025

Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Rating of “Buy” by Analysts - Defense World

Apr 16, 2025
pulisher
Apr 15, 2025

Vanguard Group Inc. Sells 28,049 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Wellington Management Group LLP Has $1.49 Million Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Apr 14, 2025
pulisher
Apr 12, 2025

KLP Kapitalforvaltning AS Makes New Investment in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

Needham & Company LLC Reiterates Buy Rating for Stoke Therapeutics (NASDAQ:STOK) - Defense World

Apr 11, 2025
pulisher
Apr 05, 2025

Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio - simplywall.st

Apr 05, 2025
pulisher
Apr 03, 2025

Stoke Therapeutics stock hits 52-week low at $6.09 amid market challenges By Investing.com - Investing.com South Africa

Apr 03, 2025
pulisher
Apr 03, 2025

Stoke Therapeutics stock hits 52-week low at $6.09 amid market challenges - Investing.com India

Apr 03, 2025
pulisher
Apr 03, 2025

Teacher Retirement System of Texas Purchases Shares of 10,219 Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Apr 03, 2025
pulisher
Apr 01, 2025

Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - Business Wire

Apr 01, 2025
pulisher
Apr 01, 2025

Revolutionary RNA Treatment for Rare Disease: Stoke CEO to Reveal Latest Progress - Stock Titan

Apr 01, 2025
pulisher
Mar 30, 2025

Swiss National Bank Acquires 11,400 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

FY2025 Earnings Forecast for STOK Issued By Chardan Capital - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Charles Schwab Investment Management Inc. Grows Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Mar 27, 2025
pulisher
Mar 26, 2025

Stoke Therapeutics stock hits 52-week low at $7.20 amid market challenges By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Stoke Therapeutics stock hits 52-week low at $7.20 amid market challenges - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

Dravet Syndrome Market Expected to Experience Major Growth - openPR.com

Mar 26, 2025
pulisher
Mar 25, 2025

Bank of New York Mellon Corp Acquires 1,330 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Mar 25, 2025
pulisher
Mar 25, 2025

(STOK) Technical Data - news.stocktradersdaily.com

Mar 25, 2025
pulisher
Mar 24, 2025

Cantor Fitzgerald Issues Positive Forecast for STOK Earnings - Defense World

Mar 24, 2025
pulisher
Mar 23, 2025

Wedbush Equities Analysts Raise Earnings Estimates for STOK - Armenian Reporter

Mar 23, 2025
pulisher
Mar 22, 2025

Earnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo

Mar 22, 2025
pulisher
Mar 22, 2025

Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

Mar 22, 2025
pulisher
Mar 22, 2025

Q1 EPS Estimates for Stoke Therapeutics Increased by Wedbush - Defense World

Mar 22, 2025
pulisher
Mar 22, 2025

Brokers Offer Predictions for STOK Q3 Earnings - Defense World

Mar 22, 2025
pulisher
Mar 22, 2025

What is Leerink Partnrs’ Forecast for STOK Q1 Earnings? - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

Stoke Therapeutics general counsel sells shares totaling $35,731 By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Chardan Capital - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Stoke Therapeutics general counsel sells shares totaling $35,731 - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

Stoke Therapeutics (NASDAQ:STOK) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Analysts Issue Forecasts for STOK Q1 Earnings - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

Stoke therapeutics’ chief medical officer sells $61,238 in stock By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Stoke Therapeutics director Kaye Edward M. sells shares worth $163,672 - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Stoke Therapeutics Executives Sell Shares for Tax Liabilities - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Stoke Therapeutics director Kaye Edward M. sells shares worth $163,672 By Investing.com - Investing.com UK

Mar 20, 2025
pulisher
Mar 20, 2025

Stoke therapeutics’ chief medical officer sells $61,238 in stock - Investing.com

Mar 20, 2025
pulisher
Mar 19, 2025

The Escalator: Stoke Therapeutics, Merck, Sutro Biopharma and more - Medical Marketing and Media

Mar 19, 2025
pulisher
Mar 19, 2025

After Securing Biogen Pact, Stoke’s CEO Edward Kaye Bows Out - insights.citeline.com

Mar 19, 2025
pulisher
Mar 19, 2025

Stoke Therapeutics announces CEO transition - The Pharma Letter

Mar 19, 2025
pulisher
Mar 19, 2025

Stoke Therapeutics Inc (STOK) Q4 Earnings: EPS of -$0.18 Beats E - GuruFocus

Mar 19, 2025
pulisher
Mar 19, 2025

Stoke Therapeutics (NASDAQ:STOK) Receives Buy Rating from Needham & Company LLC - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

Stoke Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Forecasting The Future: 7 Analyst Projections For Stoke Therapeutics - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

Ed Kaye, founding CEO of Stoke Therapeutics, steps down - The Business Journals

Mar 18, 2025
pulisher
Mar 18, 2025

Stoke Therapeutics Slips as CEO Steps Down - MSN

Mar 18, 2025
pulisher
Mar 18, 2025

Stoke Therapeutics falls as CEO steps down amid earnings beat By Investing.com - Investing.com Canada

Mar 18, 2025
pulisher
Mar 18, 2025

Stoke Therapeutics falls as CEO steps down amid earnings beat - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Stoke CEO Ed Kaye to depart shortly after inking Biogen pact and before its first Phase 3 trial - Endpoints News

Mar 18, 2025
pulisher
Mar 18, 2025

Stoke Therapeutics CEO Edward Kaye Steps Down; Interim CEO Named -March 18, 2025 at 08:02 am EDT - MarketScreener

Mar 18, 2025

Stoke Therapeutics Inc (STOK) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.04
price up icon 2.51%
$72.65
price up icon 3.49%
$32.60
price up icon 1.27%
$24.61
price up icon 6.77%
$98.76
price up icon 0.52%
biotechnology ONC
$230.98
price up icon 1.24%
大文字化:     |  ボリューム (24 時間):